Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024. 1. Discuss the data presented at ASCO 2024 on long-term follow-up of patients receiving ...

Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...

Over one third of patients with giant cell arteritis exhibit vascular inflammation even after receiving treatment with tocilizumab and glucocorticoids for at least 6 months, which suggests the need ...

INCHEON, South Korea, Oct. 2, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA ® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.

INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...

Tocilizumab exposure among patients with giant cell arteritis was not associated with increased risk for gastrointestinal perforation when compared with steroid treatment. Tocilizumab exposure among ...

With worldwide supplies of tocilizumab dwindling as the COVID-19 pandemic rages on, a shortage of the agent will persist "for at least the next several weeks," according to Genentech, the Roche unit ...